Microsoft word - 09-06-30_fjord.doc
Santhera Pharmaceuticals Holding AG Santhera’s FJORD Phase IIb Study Demonstrates Efficacy of JP-1730/Fipamezole for the Treatment of Dyskinesia in Parkinson’s Disease Liestal, Switzerland, June 30, 2009 – Santhera Pharmaceuticals (SIX: SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announced today positive data from its Phase I